Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases

Background/aim: Inflammatory bowel disease (IBD) mainly encompass two entities called ulcerative colitis (UC) and Crohn's disease (CD), both of which are chronic, progressive and, inflammatory conditions of the gastrointestinal tract. Various indicators and noninvasive markers have been sought and used in IBD patients to help assessing disease activity and treatment effectiveness although none of them are proven to yield definite results in full correlation with the clinical, endoscopic, and histopathological examinations. The aim of the current study was to investigate the relationship of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) levels with disease type and activity and to assess their potential use in establishing diagnosis and activity status of IBD, namely UC and CD. Materials and methods: A total of 111 IBD patients with determined active and inactive disease periods and 70 matched controls were recruited. Serum NGAL levels of the patients and the control group were measured using commercially available ELISA kits. ADMA and SMDA levels were measured by high performance liquid chromatography. Results: The IBD group had significantly higher serum levels of NGAL (p = 0.001), ADMA (p = 0.0001), and SDMA (p = 0.0001) in comparison to the control group. Likewise, serum NGAL, ADMA, and SDMA levels were significantly higher in the active IBD group compared to the inactive IBD group (p = 0.0001). Active UC and active CD patients similarly had significantly higher levels of serum NGAL, ADMA, and SDMA than the respective levels in inactive UK and inactive CD patients (p = 0.0001). Conclusion: Serum NGAL, ADMA and SMDA levels are increased in patients with IBD, and serum NGAL, ADMA and SMDA concentrations are significantly higher in active IBD patients than inactive IBD patients. Our results suggest these biomarkers may serve in estimating IBD activity and severity.Key words: Inflammatory bowel disease, ulcerative colitis, Crohn's disease, neutrophil gelatinase-associated lipocalin, asymmetric dimethylarginine, symmetric dimethylarginine

PDF

___

1. Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflammatory Bowel Diseases 2005; 11 (3): 304- 313. doi: 10.1097/01.mib.0000160772.78951.61
2. Hatoum OA, Miura H, Binion DG. The vascular contribution in the pathogenesis of inflammatory bowel disease. The American Journal of Physiology-Heart and Circulatory Physiology 2003; 285 (5): 1791-1796. doi: 10.1152/ajpheart.00552.2003
3. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clinical Microbiology Reviews 2002; 15 (1): 79-94. doi: 10.1128/cmr.15.1.79-94.2002
4. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115 (1): 182-205. doi: 10.1016/s0016-5085(98)70381-6
5. Yeşil A, Gönen C, Şenates E, Paker N, Gökden Y et al. Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. Digestive Diseases and Sciences 2013; 58 (9): 2587-2593. doi: 10.1007/s10620-013-2676-z
6. Vilela EG, Torres HODG, Martins FP, Ferrari MLA, Andrade MM et al. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World Journal of Gastroenterology 2012; 18 (9): 872-881. doi: 10.3748/wjg.v18.i9.872
7. Dowsett L, Higgins E, Alanazi S, Alshuwayer NA, Leiper FC et al. ADMA: a key player in the relationship between vascular dysfunction and inflammation in atherosclerosis. Journal of Clinical Medicine 2020; 9 (9): 3026. doi: 10.3390/jcm9093026
8. Tain YL, Hsu CN. Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Toxins 2017; 9 (3): 92. doi: 10.3390/toxins9030092
9. Erbil MK, Kurt YG, Yaman H. Çakır E, Akgül EÖ et al. Metabolism of asymmetric dimethylarginine and its clinical significance. Turkish Journal of Biochemistry 2012; 37 (1): 99–105. doi:
10.5505/tjb.2012.76486 10. Böger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clinical Chemistry Laboratory Medicine 2003; 41 (11): 1467-1472. doi: 10.1515/CCLM.2003.225
11. Cooke JP. Does ADMA cause endothelial dysfunction? Arteriosclerosis, Thrombosis, and Vascular Biology 2000; 20 (9): 2032-2037. doi: 10.1161/01.atv.20.9.2032
12. Xu SY, Carlson M, Engström A, Garcia R, Peterson CGB et al. Purification and characterization of a human neutrophil lipocalin (HNL) from secondary granules of human neutrophils. Scandinavian Journal of Clinical and Laboratory Investigation 1994; 54 (5): 365-376. doi: 10.3109/00365519409088436
13. Seveus L, Amin K, Peterson CB, Roomans GM, Venge P. Human neutrophil lipocalin (HNL) is a specific granule constituent of the neutrophil granulocytes. Studies in bronchial and lung parenchymal tissue and peripheral blood cells. Histochemistry and Cell Biology 1997; 107: 423-433. doi: 10.1007/s004180050129
14. Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology (Carlton) 2010; 15 (4): 419-428. doi: 10.1111/j.1440-1797.2010.01317.x
15. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Molecular Cell 2002; 10 (5): 1033-1043. doi: 10.1016/s1097- 2765(02)00708-6
16. Yang J, Goetz D, Li JY, Wang W, Mori WK et al. An iron delivery pathway mediated by a lipocalin. Molecular Cell 2002; 10 (5): 1045-1056. doi: 10.1016/s1097-2765(02)00710-4
17. Nielsen OH, Gionchetti P, Ainsworth M, Vainer B, Campieri M et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. American Journal of Gastroenterology 1999; 94 (10): 2923-2928. doi: 10.1111/j.1572-0241.1999.01439.x
18. Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology inflammation, established markers, and disease activity. Journal of Gastroenterology 2012; 47 (5): 519- 530. doi: 10.1007/s00535-011-0516-5
19. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. British Medical Journal 1955; 29 (2): 1041-1048. doi: 10.1136/bmj.2.4947.1041
20. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. British Medical Journal 1989; 298 (6666): 82-86. doi: 10.1136/bmj.298.6666.82
21. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70 (3): 439-444.
22. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods 2007; 39 (2): 175-191. doi: 10.3758/bf03193146
23. Budzynska A, Gawron-Kiszka M, Nowakowska-Dulawa E, Spiewak J, Lesinska M et al. Serum neutrophil gelatinaseassociated lipocalin (NGAL) correlates with clinical and endoscopic activity in ulcerative colitis but fails to predict activity in Crohn’s disease. Journal of Physiology and Pharmacology 2017; 68 (6): 859-865.
24. Thorsvik S, Damas JK, Granlund vBA, Flo TH, Bergh K et al. Fecal neutrophil gelatinase‐associated lipocalin as a biomarker for inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2017; 32 (1): 128-135. doi: 10.1111/jgh.13598
25. Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G et al. The role of intestinal microbiota and the immune system. European Review for Medical and Pharmacological Sciences 2013; 17 (3): 323-333.
26. Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. Journal of Gastroenterology 2013; 48 (3): 315-321. doi: 10.1007/s00535-013-0777-2
27. Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125 (1): 58-69. doi: 10.1016/s0016-5085(03)00699-1
28. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8- Iso-Prostaglandin F2a (8-iso-PGF2a) level in patients with inflammatory bowel diseases. Inflammatory Bowel Diseases 2010; 16 (1): 52-57. doi: 10.1002/ibd.20994
29. Korpacka MK, Fleszar MG, Misa IB, Lewandowski L, Szczuka I et al. Transcriptional and metabolomic analysis of LArginine/Nitric Oxide pathway in inflammatory bowel disease and its association with local inflammatory and angiogenic response: preliminary findings. International Journal of Molecular Sciences 2020; 21 (5): 1641; doi:10.3390/ijms21051641
30. Boelaert J, Schepers E, Glorieux, G, Eloot S, Vanholder R et al. Determination of asymmetric and symmetric dimethylarginine in serum from patients with chronic kidney disease: UPLCMS/MS versus ELISA. Toxins (Basel) 2016; 8 (5): 149. doi: 10.3390/toxins8050149
31. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology 2010; 105 (1): 162-169. doi: 10.1038/ajg.2009.545
32. Vucelic B. Inflammatory bowel diseases: controversies in the use of diagnostic procedures. Digestive Diseases 2009; 27 (3): 269-277. doi: 10.1159/000228560